Neurodegenerative Disease Market, By Indication Type (Parkinson\'s Disease, Alzheimer\'s Disease, Multiple Sclerosis, Huntington Disease, and Other Indication Types), By Drug Type (N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, and Other Drug Types), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)-

Published In : Mar 2023

Code : CMI1860

Pages :172

Formats :

Excel and PDF

Industry : Pharmaceutical

Leading Companies

Global Neurodegenerative Disease Market: Key Developments

In June 2021, UniQure enrolled the first two patients in the higher-dose second cohort of a Phase I/II clinical trial in the United States for AMT-130, a micro ribonucleic acid (miRNA) gene therapy developed as a potential treatment for Huntington’s disease (HD).

In March 2021, Janssen Pharmaceutical received the United States Food and Drug Administration (FDA) approval for Ponvory (ponesimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome.

In October 2020, SK Chemical launched Ongentis, a Parkinson's disease treatment developed by the Portuguese pharmaceutical firm Bial. It was the first time a third- generation COMT (Catechol O-methyltransferase) inhibitor that contains Opicapone has been released in Korea.

In September 2020, Genentech announced the initiation of Phase III clinical trial program for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial program for Ocrevus (ocrelizumab) and a distinct Ocrevus trial to support African-American and Hispanic- and Latinx-American patients with MS.

Global Neurodegenerative Disease Market: Key Companies Insights

The global neurodegenerative disease market is highly competitive. This is attributed to the rise in burden of neurodegenerative diseases and growing geriatric population, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global neurodegenerative disease market are Abbvie Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International Gmbh, F. Hoffmann-La Roche, and Merck & Co. Inc., among others.